Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Giant Cell Arteritis

Conditions

Giant Cell Arteritis

Trial Timeline

Sep 29, 2022 → Feb 24, 2026

NCT ID

NCT05380453

About Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.

Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c. is a phase 3 stage product being developed by Novartis for Giant Cell Arteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT05380453. Target conditions include Giant Cell Arteritis.

What happened to similar drugs?

5 of 13 similar drugs in Giant Cell Arteritis were approved

Approved (5) Terminated (3) Active (6)

✅PexidartinibDaiichi SankyoApproved

✅Tocilizumab + PrednisoneRocheApproved

✅ValganciclovirRocheApproved

✅DenosumabAmgenApproved

✅XGEVA®AmgenApproved

🔄PexidartinibDaiichi SankyoPhase 3

🔄Upadacitinib + Corticosteroid (CS)AbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05380453	Phase 3	Completed	Sep 29, 2022	Feb 24, 2026	Giant Cell Arteritis

Competing Products

20 competing products in Giant Cell Arteritis

See all competitors

Product	Company	Stage	Hype Score
prednisone	Kiniksa Pharmaceuticals	Phase 2	29
Pexidartinib	Daiichi Sankyo	Phase 2	39
Pexidartinib	Daiichi Sankyo	Phase 3	44
Pexidartinib	Daiichi Sankyo	Approved	43
Baricitinib	Eli Lilly	Phase 2	35
Upadacitinib + Corticosteroid (CS)	AbbVie	Phase 3	40
dovitinib	Novartis	Phase 2	35
Secukinumab 300 mg, s.c. + Prednisolone + Placebo	Novartis	Phase 2	35
Secukinumab	Novartis	Phase 1	29
Secukinumab 300 mg + Secukinumab 150 mg	Novartis	Phase 3	40
Tocilizumab + Placebo	Roche	Phase 3	44
Tocilizumab + Prednisone	Roche	Approved	43
Tocilizumab	Roche	Phase 3	40
Tocilizumab	Roche	Phase 1	29
Valganciclovir	Roche	Approved	35
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate	Roche	Phase 3	40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)	Roche	Phase 2	35
tocilizumab and IV steroids combination	Roche	Phase 2	31
Denosumab	Amgen	Approved	43
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]	Amgen	Phase 2	27